China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to proceed with a Phase III study for its drug candidate JSKN033. The study will compare JSKN033 against the investigator’s choice of chemotherapy in the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
JSKN003: A HER2-Targeted ADC with Enhanced Stability and Efficacy
JSKN003 is a HER2-targeted antibody drug conjugate (ADC) that has demonstrated better serum stability and a stronger bystander killing effect in preclinical studies. The drug is currently subject to multiple clinical studies in China and Australia, with results showing good tolerability and safety profiles.
Significant Therapeutic Effects in Advanced Solid Tumors
JSKN003 has an expanded treatment window and has shown significant therapeutic effects in patients with various advanced solid tumors who have undergone multiple lines of systemic treatment. Particularly, the drug has shown promise in patients with HER2-expressing breast cancer, platinum-resistant ovarian cancer, and solid tumors with high HER2 expression.-Fineline Info & Tech
